Navigation Links
InterMune Reports Fourth Quarter And Full Year 2012 Financial Results And Business Highlights
Date:2/21/2013

ures before complete patient access to Esbriet is achieved.
  • Mid-Sized Countries (MSC) – In addition to the seven MSC for which Esbriet pricing has been secured, the company anticipates launches in the remaining three MSC of Netherlands, Finland and Ireland by mid-2013, assuming that acceptable pricing and reimbursement conditions are negotiated in these countries.
  • Enrollment of InterMune's Phase 3 pirfenidone study, ASCEND, in the United States and certain additional territories was completed in January 2013.  ASCEND is a double-blind, placebo-controlled trial of 52 weeks duration with a primary endpoint of change in forced vital capacity (FVC) between baseline and Week 52.  The trial enrolled IPF patients with mild-to-moderate impairment in lung function and certain characteristics that the company believes enhance the probability of a successful study outcome.  Top-line results are expected in Q2 of 2014.
  • On January 22, 2013, InterMune completed a public offering of 15,525,000 shares of its common stock, including the underwriters' over-allotment, with net proceeds to the company of $145.7 million (after payment of underwriting discounts and commissions, and expenses).  InterMune also completed a concurrent public offering of $120.75 million aggregate principal amount of the company's 2.50% convertible Senior Notes due 2017, including the Note underwriters' over-allotment, with net proceeds to the company of $116.7 million (after payment of the underwriting discounts and commissions, and expenses).  The company has used proceeds from the convertible notes offering to repurchase and cancel $66.6 million of its outstanding $85.0 million aggregate principal amount 2015 Notes, and intends to repurchase the remaining $18.4 million of the outstanding 2015 Notes over time.
  • On February 14, 2013 InterMune announced that Sean P. Nolan has joined the company as Executive Vice President and Chief B
    '/>"/>

  • SOURCE InterMune, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10

    Related biology technology :

    1. InterMune to Report Unaudited Fourth Quarter EsbrietĀ® Revenue and Business Update on January 5
    2. InterMune to Present at J. P. Morgan Healthcare Conference
    3. InterMune to Release Fourth Quarter and Full Year Financial Results on February 9
    4. InterMune To Present At JMP Securities Healthcare Conference
    5. InterMune To Release Third Quarter Financial Results On November 7
    6. InterMune Reports Third Quarter 2012 Financial Results And Business Highlights
    7. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
    8. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
    9. Interleukin Genetics Reports Third Quarter 2011 Financial Results
    10. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
    11. Nile Therapeutics Reports 2011 Third Quarter Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/29/2015)... ... July 29, 2015 , ... Asymmetrex, LLC ... progress in evaluating the full range of capabilities of its unique cache of ... cells perform the day-to-day renewal and repair of normal tissues and organs. This ...
    (Date:7/28/2015)... July 28, 2015  PDL BioPharma, Inc. (PDL, or ... the Company will release its second quarter 2015 financial ... Wednesday, August 5, 2015, after market close. PDL,s management ... at 4:30 p.m. Eastern Time to discuss the financial ... be available via the webcast link on the PDL ...
    (Date:7/28/2015)... 21, 2015 Research and Markets ( ... "Biomedical Refrigerators and Freezers Market - Global ... 2014 - 2022" report to their offering. ... freezers market has been segmented based on applications: ... and others. The others segment includes applications of ...
    (Date:7/28/2015)... , July 28, 2015  Moerae Matrix Inc. ... 1 clinical trial with MMI-0100, a first-in-class inhibitor ... developed for pulmonary disorders characterized by inflammation and ... United Kingdom , is a double-blind, two-way ... the safety and tolerability of MMI-0100 when given ...
    Breaking Biology Technology:Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 2Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 3Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 4PDL BioPharma to Announce Second Quarter 2015 Financial Results on August 5, 2015 2Biomedical Refrigerators and Freezers Market Report - Global Industry Analysis 2015 2Biomedical Refrigerators and Freezers Market Report - Global Industry Analysis 2015 3Moerae Initiates Lipopolysaccharide (LPS) Challenge Study of Inhaled MMI-0100 for Pulmonary Disease Following Encouraging Safety and Tolerability Observed in Single Ascending Dose Phase 1 Study 2
    ... , ... Specialist Segmentation Module explores how oncologists use the Internet and other technologies for professional ... ... than the overall population of U.S. physicians to visit pharmaceutical, biotech, and device corporate ...
    ... , , , PHILADELPHIA, ... technologies for biomedical research, molecular diagnostics and personalized medicine, today ... have joined the company,s advisory team. Dr. Lee is ... at Brigham and Women,s Hospital, Harvard Medical School and the ...
    ... HOERSHOLM, Denmark and SAN DIEGO, California, September 16 /PRNewswire/,-- , ... Leading RNA Industry Expert,Art Levin Ph.D. as President of US ... - Utilizing its Proprietary RNA Chemistry - Locked Nucleic Acid ... Relationships,With New Partners, Increase Visibility With Capital Markets and Attract,Leading ...
    Cached Biology Technology:Oncologists Visit Pharma Sites and Post Professional Content Online More Frequently than the Average Physician 2Oncologists Visit Pharma Sites and Post Professional Content Online More Frequently than the Average Physician 3Oncologists Visit Pharma Sites and Post Professional Content Online More Frequently than the Average Physician 4BioNanomatrix Appoints Genomic Research Experts Charles Lee and David L. Barker as Advisers 2BioNanomatrix Appoints Genomic Research Experts Charles Lee and David L. Barker as Advisers 3BioNanomatrix Appoints Genomic Research Experts Charles Lee and David L. Barker as Advisers 4New Collaborations and Breakthrough Advancements in RNA-Based Drug Development Programs Lead Santaris Pharma A/S to Establish US Operations 2New Collaborations and Breakthrough Advancements in RNA-Based Drug Development Programs Lead Santaris Pharma A/S to Establish US Operations 3New Collaborations and Breakthrough Advancements in RNA-Based Drug Development Programs Lead Santaris Pharma A/S to Establish US Operations 4
    (Date:7/21/2015)... Today, ZTE announced its Android smartphone Axon, featuring FPC,s touch ... 2015 that relate to sales of FPC1025 for this smartphone model ... for 2015. Jörgen Lantto, CEO of FPC, comments: " ... China and we are proud that ZTE ... Axon , its first smartphone ...
    (Date:7/13/2015)... Jul. 13, 2015 NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce ... patent 62/188684 for BEHAVIORAL-DIRECTED AUTHENTIATION METHOD ... convenient and secure method to make payments.  With ... methods, introduced with its groundbreaking voice-direct payment patent ...
    (Date:7/8/2015)... 8, 2015 Summary Pancreatic cancer is ... most fatal, with a mortality rate of 10.9 deaths ... pancreatic cancer patients has highlighted a significant need for ... being met by the current market. A highly ... with varying molecule types and mechanisms of action, which ...
    Breaking Biology News(10 mins):FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3
    ... image, processing technology to the difficult challenge of rapidly collecting ... ... Aware, Inc. (Nasdaq:,AWRE), a global provider of imaging and ... software,development kits used to perform rapid autocapture and compliance assurance,of ...
    ... Microscopic worms used for scientific research are living longer ... on how the human body ages and how doctors ... cause inherited diseases, according to a new University of ... study of its kind, researchers manipulated the metabolic state ...
    ... p.m. to 7:30 p.m. , The New York Academy ... 40th Floor, New York, NY 10007 The Malaria ... Public Health and The New York Academy of Sciences ... half-day symposium to highlight the latest research developments in ...
    Cached Biology News:Aware, Inc. Introduces Biometrics Software for Tenprint Autocapture 2Aware, Inc. Introduces Biometrics Software for Tenprint Autocapture 3CU-Boulder worm study sheds light on human aging, inherited diseases 2CU-Boulder worm study sheds light on human aging, inherited diseases 3Progress Against Malaria: Developments on the Horizon 2
    ... , Customer Peptide Synthesis , 20 Amino Acid length ... 20 mg will return to customer for future usage conjugation ... , Maintenance 102 days/each , ... x5 /each , Test bleed (app. 5 ml) ...
    Request Info...
    ... This Kit Contains the following: , Coated Capture ... sealers , Wash/Sample Diluent: 300 mL of 2X ... vial 10 microg lyophilized peptide , Lyophilized Standard ... of 50X concentrate , Secondary Antibody-HRP: 30 microL ...
    ...
    Biology Products: